Alembic Pharma Q2 FY27: Revenue Surges 36% to ₹2,603 Cr, PAT Jumps 81% YoY
Alembic Pharmaceuticals reported strong Q2 FY27 results with revenue up 36% YoY to ₹2,603 Cr and PAT up 81% YoY to ₹335 Cr. US Formulations grew 77% to ₹1,003 Cr, while India Branded business grew 14% to ₹725 Cr. API business increased 39% to ₹436 Cr. An investor call is scheduled for November 4, 2026.
The announcement details strong financial performance with substantial year-on-year growth in key metrics like revenue and profit, alongside positive operational highlights across major business segments (US, India, API), indicating a significant positive impact on the company's outlook.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with positive commentary from the Managing Director about strong execution and future positioning.
Alembic Pharmaceuticals Limited has announced its consolidated financial results for the second quarter and half-year ended September 30, 2026. The company reported a strong performance with revenue from operations increasing by 36% year-on-year to ₹2,603 crore. EBITDA saw a significant jump of 78% year-on-year to ₹578 crore, achieving a margin of 22%. Profit After Tax (PAT) stood at ₹335 crore, an impressive 81% increase year-on-year.
Mr. Pranav Amin, Managing Director, expressed satisfaction with the broad-based growth and improved profitability, highlighting strong execution across markets. He noted exceptional performance in the US business, driven by volume growth and new launches, and a regained momentum in India. The company is encouraged by the traction in its US Branded portfolio and the improving momentum in chronic therapies in India Branded business. Alembic Pharmaceuticals is well-positioned to sustain growth and create long-term value.
Operationally, the India Branded Business grew 14% YoY to ₹725 crore, with robust growth in Gynecology, Cardiology, Gastrology, and Ophthalmology. The Animal Health segment continued its growth momentum with 23% growth. In the International Business, US Formulations grew by 77% to ₹1,003 crore, with three launches during the quarter. Ex-US business grew by 12% to ₹440 crore, and the company received one ANDA approval, bringing the cumulative approvals to 245. The API business also showed strong growth, increasing by 39% to ₹436 crore.
Total revenue for the quarter was ₹2,603 crore, a 36% increase from the previous year. For the half-year ended September 30, 2026, total revenue was ₹4,753 crore, up 31% YoY. The company will host an investor call on November 4, 2026, at 5:00 PM IST to discuss performance.
What to do with a filing like this
Alembic Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alembic Pharmaceuticals Limited. Read the original for the full detail.